Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP, Finance & CFO | February 28, 2017 | March 03, 2017 |
| Sonoma Pharmaceuticals, Inc.SNOA · Entity 8177 | Director | March 01, 2018 | March 02, 2018 |
| Yarrow Bioscience, Inc.VYNE · Entity 6871 | Director | December 12, 2025 | December 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date February 28, 2017 · Filed March 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,323 |
Ending reported balance
After 2017-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-02-28 · Grant · Acquired 18,750 · Balance 47,640 Row 2 · 2017-02-28 · Tax withholding · Disposed 7,317 · Balance 40,323 |
Sonoma Pharmaceuticals, Inc.
Report date March 01, 2018 · Filed March 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 43,417 |
Reported balance
After 2018-03-01 transaction · row 1
1 source rowRow 1 · 2018-03-01 · Grant · Acquired 1,424 · Balance 43,417 F1: The stock was granted by the Issuer as a quarterly retainer pursuant to the Non-Employee Director Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock was granted by the Issuer as a quarterly retainer pursuant to the Non-Employee Director Compensation Plan.
Yarrow Bioscience, Inc.
Report date December 12, 2025 · Filed December 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2035-12-11 | Direct | 20,000 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 20,000 · Balance 20,000 F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AGILE THERAPEUTICS INC
Report date August 26, 2024 · Filed August 26, 2024
Section 16 reporting ended · disclosed 2024-08-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-26 transaction · row 1
1 source rowRow 1 · 2024-08-26 · Disposition to issuer · Disposed 973 · Balance 0 F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 973 shares of Common Stock were converted into the right to receive into the right to receive a cash payment of $1.52 (the "Merger Consideration") per share of Common Stock, for an aggregate of $1,479, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 973 shares of Common Stock were converted into the right to receive into the right to receive a cash payment of $1.52 (the "Merger Consideration") per share of Common Stock, for an aggregate of $1,479, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person
Foamix Pharmaceuticals Ltd.
Report date March 09, 2020 · Filed March 11, 2020
Section 16 reporting ended · disclosed 2020-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.66 · Expires 2029-05-16 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-09 · Disposition to issuer · Disposed 49,412 · Balance 0 F2: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F3: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. F4: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F1: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020.
F2: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2)
F3: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement.
F4: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2025 Filed Dec 15, 2025 16:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001240499-25-000004 · form4-12152025_041201.xml · derivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-12-11 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 16:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-24-029289 · form4-12132024_041213.xml · derivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-12-11 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 17:35 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Disposition to issuerCommon Stock | 973 | $1.52 | $1,478.96 |
DisclosureSEC source: 0001104659-24-092940 · tm2422466-5_4seq1.xml · nonDerivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 973 shares of Common Stock were converted into the right to receive into the right to receive a cash payment of $1.52 (the "Merger Consideration") per share of Common Stock, for an aggregate of $1,479, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 17:09 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001209191-24-000459 · doc4.xml · derivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-31 F1 · derivative.exercise_date: The shares subject to the option vest on January 1, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 17:01 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-23-058807 · doc4.xml · derivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-12 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest on December 13, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 17:08 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,065 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0000929638-23-001706 · form4.xml · derivative · entry 2 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,065 Underlying: Common Stock · 1,065 shares Expires 2033-06-07 F3 · derivative.exercise_date: This option was granted on June 8, 2023 and vests in full on June 8, 2024, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 17:08 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 935 | $0.00 | $0.00 |
DisclosureSEC source: 0000929638-23-001706 · form4.xml · nonDerivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 974 F1 · shares: These shares represent restricted stock units that were granted on June 8, 2023, which will vest and be settled in common stock on June 8, 2024, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. F2 · balance_after: On April 10, 2023 the Issuer completed a one-for-fifty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 17:10 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 20,500 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001209191-22-045648 · doc4.xml · derivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2032-08-10 F1 · derivative.exercise_date: Represents the annual award to non-executive directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest over a 12-month period in equal, monthly installments, ending August 10, 2023. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:49 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 807 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001104659-22-070184 · tm2218213-7_4seq1.xml · derivative · entry 2 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 807 Underlying: Common Stock · 807 shares Expires 2032-06-08 F3 · derivative.exercise_date: This option was granted on June 9, 2022 and vests in full on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 16:49 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 670 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-070184 · tm2218213-7_4seq1.xml · nonDerivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,952 F1 · shares: These shares represent restricted stock units that were granted on June 9, 2022, which will vest and be settled in common stock on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. F2 · balance_after: On April 26, 2022, the Issuer completed a one-for-forty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 17:04 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 20,500 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001209191-21-047405 · doc4.xml · derivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2031-07-19 F1 · derivative.exercise_date: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 19:11 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 29,905 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001104659-21-079619 · tm2119345-6_4seq1.xml · derivative · entry 2 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,905 Underlying: Common Stock · 29,905 shares Expires 2031-06-07 F2 · derivative.exercise_date: The option was granted on June 8, 2021 and vests in full on June 8, 2022, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 19:11 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 24,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-079619 · tm2119345-6_4seq1.xml · nonDerivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,296 F1 · shares: These shares represent restricted stock units that were granted on June 8, 2021, which will vest and be settled in common stock on June 8, 2022, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 17:00 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionStock Options · Derivative | 75,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001209191-20-047960 · doc4.xml · derivative · entry 2 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,971 Underlying: Common Stock · 75,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options vested over a 12 month period, in equal, quarterly installments, ending May 16, 2020. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 17:00 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Exercise / conversionCommon Stock | 75,000 | $1.48 | $111,000.00 |
DisclosureSEC source: 0001209191-20-047960 · doc4.xml · nonDerivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:37 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 22,500 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-20-045128 · doc4.xml · derivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2030-08-03 F1 · derivative.exercise_date: These options vest over a 12 month period in equal, quarterly installments, ending August 3, 2021. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:20 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 45,212 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001104659-20-072483 · a4.xml · derivative · entry 2 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,212 Underlying: Common Stock · 45,212 shares Expires 2030-06-08 F2 · derivative.exercise_date: The option was granted on June 9, 2020 and vests in three equal annual installments beginning on June 9, 2021, subject to the Reporting Person's continued service on the Issuer's board of directors through each vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during each respective year of board service. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:20 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 26,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-072483 · a4.xml · nonDerivative · entry 1 BARBARI SHARON · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,786 F1 · shares: These shares represent restricted stock units that were granted on June 9, 2020, which will vest and be settled in common stock in three equal annual installments beginning on June 9, 2021, subject to the Reporting Person's continued service on the Issuer's board of directors through each vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during each respective year of board service. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:43 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 45,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001209191-20-020656 · doc4.xml · derivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The option will vest and become exercisable as to 1/3rd of the shares subject to the option on each annual anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:54 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 29,271 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001209191-20-018220 · doc4.xml · derivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,271 Underlying: Common Stock · 29,271 shares Expires 2029-05-16 F2 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F1 · derivative.exercise_date: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:36 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 49,412 | Not disclosed Strike: $2.66 | Not disclosed |
DisclosureSEC source: 0001209191-20-018190 · doc4.xml · derivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 49,412 shares Expires 2029-05-16 F2 · price: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F3 · price: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. F4 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F1 · derivative.exercise_date: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020. Read SEC document |
| May 16, 2019 Filed May 20, 2019 18:27 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOptions · Derivative | 49,412 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-19-031522 · doc4.xml · derivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,412 Underlying: Ordinary Shares · 49,412 shares Expires 2029-05-16 F1 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F2 · derivative.exercise_date: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 19:13 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantCommon Stock, $0.0001 par value per share | 1,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-18-000575 · barbari_f4-030118.xml · nonDerivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,417 F1 · price: The stock was granted by the Issuer as a quarterly retainer pursuant to the Non-Employee Director Compensation Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:39 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantCommon Stock, $0.0001 par value per share | 17,211 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-18-000036 · barbari_f4.xml · nonDerivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,993 F1 · price: The stock was granted by the Issuer as a bonus for services and vests immediately. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 16:39 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantCommon Stock, $0.0001 par value per share | 13,944 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-17-003203 · barbari_f4.xml · nonDerivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,782 F1 · price: The stock was granted by the Issuer as a quarterly retainer as well as an annual grant pursuant to the Non-Employee Director Compensation Plan. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 18:53 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantCommon Stock, $0.0001 par value per share | 880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-17-002258 · barbari_f4.xml · nonDerivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,838 F1 · price: The stock was granted by the Issuer as a quarterly retainer pursuant to the Non-Employee Director Compensation Plan. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 08:29 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantCommon Stock, $0.0001 par value per share | 754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-17-001456 · barbari_frm4.xml · nonDerivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,958 F1 · price: The stock was granted by the Issuer as a quarterly retainer pursuant to the Non-Employee Director Compensation Plan. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 16:06 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantCommon Stock, $0.0001 par value per share | 710 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-17-000477 · barbari_f4.xml · nonDerivative · entry 2 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,204 F2 · price: The stock was granted by the Issuer as a quarterly retainer pursuant to the Non-Employee Director Compensation Plan. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 7,317 | $10.60 | $77,560.20 |
DisclosureSEC source: 0001061983-17-000019 · edgardoc.xml · nonDerivative · entry 2 BARBARI SHARON SURREY · CIK 0001240499 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,323 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 18,750 | $0.00 | $18.75 |
DisclosureSEC source: 0001061983-17-000019 · edgardoc.xml · nonDerivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,640 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 16:06 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantCommon Stock, $0.0001 par value per share | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-17-000477 · barbari_f4.xml · nonDerivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,494 F1 · price: The stock was granted by the Issuer as an annual grant pursuant to the Non-Employee Director Compensation Plan. Read SEC document |
| November 29, 2016 Filed Nov 30, 2016 16:57 UTC | Sonoma Pharmaceuticals, Inc. OCLS · Entity 8177 | GrantCommon Stock, $0.0001 par value per share | 1,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-16-000813 · barbari_frm4.xml · nonDerivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,244 F1 · price: The stock was granted by the Issuer as a quarterly retainer pursuant to the Non-Employee Director Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.